IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

PD-L1 expression by tumor cell lines: A predictive marker in melanoma

(2018) Anne C. Knol et al.   EXPERIMENTAL DERMATOLOGY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma

(2018) Xiang-Yang Yu et al.   Journal of Thoracic Disease

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

(2018) Na Luo et al.   OncoImmunology

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma

(2018) Wenjing Xiao et al.   EBioMedicine

p53 Isoforms and Their Implications in Cancer

(2018) Maximilian Vieler et al.   Cancers

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas

(2018) Silke Appenzeller et al.   CANCER

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis

(2018) Yi Ming Weng et al.   OncoTargets and Therapy

PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression

(2017) Stefan Kraft et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Census and evaluation of p53 target genes

(2017) M Fischer   ONCOGENE

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

(2017) Valentina Audrito et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

The Transcriptional Landscape of p53 Signalling Pathway

(2017) Chizu Tanikawa et al.   EBioMedicine

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma

(2017) Cathrin Ritter et al.   Scientific Reports

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

(2016) Zuguang Gu et al.   BIOINFORMATICS

Advances in immunotherapy for melanoma

(2016) Jason M. Redman et al.   BMC Medicine

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements

(2016) Huaiyu Mi et al.   NUCLEIC ACIDS RESEARCH

miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

(2016) Shaohua Xu et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Regulation of cytotoxic T-cell responses by p53 in cancer

(2016) Mitchell W. Braun et al.   Translational Cancer Research

NF1 Mutations Are Common in Desmoplastic Melanoma

(2015) Thomas Wiesner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

(2015) Yu Fujita et al.   MOLECULAR THERAPY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data

(2015) Antonio Colaprico et al.   NUCLEIC ACIDS RESEARCH

Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53

(2015) K. W. Yoon et al.   SCIENCE

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

p53 and NF-κB Coregulate Proinflammatory Gene Responses in Human Macrophages

(2014) Julie M. Lowe et al.   CANCER RESEARCH

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes

(2014) A.-Y. Gong et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

TCPA: a resource for cancer functional proteomics data

(2013) Jun Li et al.   NATURE METHODS

Targeting p53 in melanoma

(2013) Neil F. Box et al.   Pigment Cell & Melanoma Research

p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1

(2013) Bei Wang et al.   Nature Communications

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding

(2011) Weipeng Wang et al.   HUMAN MUTATION

An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells

(2011) Roland Houben et al.   INTERNATIONAL JOURNAL OF CANCER

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays

(2011) Roland Houben et al.   PLoS One

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Transcription-independent p53 apoptosis: an alternative route to death

(2009) Daniel Speidel   TRENDS IN CELL BIOLOGY

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols

Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats

(2008) M. J. Herold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells

(2008) L. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA